Mientras tanto, con menos discusión el lopinavir/ritonavir demostró ser ineficaz https://t.co/rkhwUEKwfu y países como EEUU relegaron su uso a la investigación. https://t.co/qIYQufy1tA https://t.co/hNTAdiLGOT
@DrSamuelBrown Kaletra trial was decent, right? (And negative) Feels like ages ago https://t.co/h3pADrZqS8
COVID 19=Kaletra(Lopinavir/Ritonavir) Ensayo(trial)en adultos hospitalizados con severo Covid19,no muestra claro beneficio. https://t.co/clGiTotVMK
RT @_AndresBlanco_: Por otra parte un estudio randomizado y controlado dejó por fuera Lopinavir/Ritonavir. Otra de las herramientas que usá…
Por otra parte un estudio randomizado y controlado dejó por fuera Lopinavir/Ritonavir. Otra de las herramientas que usábamos en conjunto con Hidroxicloroquina +/- macrólidos. https://t.co/SK1qDlEgWe
@melquiadess @norabar @RoxanaTabakman @alefolgarait @LucasViano @MLoewy @msalnacion No he visto cambios desde que se publicó. No hay citas que justifiquen el Lopinavir/ritonavir mientras ya hay evidencia negativa https://t.co/rkhwUEKwfu y se cita un estudi
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 https://t.co/6nihXQm9hX
@LucasViano @norabar @MLoewy @alefolgarait @msalnacion Del Lopinavir/Ritonavir ya sabemos que no sería eficaz. https://t.co/rkhwUF2772
RT @potrckopirot: @MarijaBogdanov4 и без секирања, знали су за лек од првог дана: https://t.co/xkU57dSGkd Само је требало неко време да не…
報告書: 重度の新型コロナウイルス感染症で入院した成人患者を対象としたロピナビル・リトナビル配合剤の臨床試験 https://t.co/Gke25w2ktu ロピナビル・リトナビル:カレトラ(アッヴィ社)
No obstante, un ensayo aleatorizado, controlado y abierto de Lopinavir-Ritonavir (https://t.co/oyT0WyP9ZL), no encontró que los fármacos redujeran la carga viral de #SARSCoV2 o produjeran un beneficio clínico en 199 pacientes graves tratados en un hospital
@martinebillen58 @JoshuaPotash Dr. Montagnier said it. They either hid the facts, or they are not fit to be leaders... https://t.co/xkU57dSGkd
@DaZivimSan @ZoraZoric3 ACE2 ензим... ал' има лека (за Сиду) и ради: https://t.co/xkU57dSGkd
@MarijaBogdanov4 и без секирања, знали су за лек од првог дана: https://t.co/xkU57dSGkd Само је требало неко време да независне клинике фођу до сазнања...
RT @cispt2: @lisamjarvis Here is trial info: https://t.co/J8xsSRtNWE BUT this paper shows that Lopinavir & Ritonavir don't actually inhib…
@lisamjarvis Here is trial info: https://t.co/J8xsSRtNWE BUT this paper shows that Lopinavir & Ritonavir don't actually inhibitor the SARS-CoV-2 protease https://t.co/CnpuB8QwmF
RT @drjavierfarina: 1/6 Tratamientos ante COVID19 Desmenuzando los estudios randomizados Iniciamos con: Lopinavir/ritonavir vs Tto estánda…
RT @WesElyMD: New #COVID19 Trials- Tx w combo-anti-HIV drugs no-go in NEJM https://t.co/Vny89JejJT BUT open label of same Lopin-Ritonavir +…
RT @MarceloHelguera: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | NEJM https://t.co/GrDRoO9iaz
@SuzanaStambol @V_MadnessMaster Напада ензим ACE2, који се налази на површини слузокоже:срца,јетре,бубрега, плућа,црева и крвних судова.Вирусни миокардитис, тромбоеболија и још милион компликација.Срећа у несрећи је што има секвенцу РНК вируса ХИВ, па Лопи
RT @AnaBandar: ثالثا: Kaletra علاجين للإيدز هما Lopinavir / Ritonavir تصنعه شركة أمريكية تمت تجربته على 199 مريض كورونا وما فاد 🥺 https://…
RT @MathieuMolimard: #Lopinavir–#Ritonavir n'ont pas montré de supériorité par rapport au traitement standard sur #COVID19 arrrêtons de les…
RT @peripatetical: Lopinavir/r not associated with improved mortality or time to recovery in severe COVID. N=199; possible smaller benefit,…
RT @drjavierfarina: 1/6 Tratamientos ante COVID19 Desmenuzando los estudios randomizados Iniciamos con: Lopinavir/ritonavir vs Tto estánda…
RT @peripatetical: Lopinavir/r not associated with improved mortality or time to recovery in severe COVID. N=199; possible smaller benefit,…
RT @peripatetical: Lopinavir/r not associated with improved mortality or time to recovery in severe COVID. N=199; possible smaller benefit,…
RT @peripatetical: Lopinavir/r not associated with improved mortality or time to recovery in severe COVID. N=199; possible smaller benefit,…
//How about the combination of #remdesivir with #Kaletra -there was a weak signal in the NEJM trial for early patients put on treatment early?// Sometimes I know something. This time I know absolutely nothing! Knowing ZERO can be a good thing sometime! #L
https://t.co/eyUrZCNe78 @nirajvasavada. One more treatment failed to show benefit.
RT @peripatetical: Lopinavir/r not associated with improved mortality or time to recovery in severe COVID. N=199; possible smaller benefit,…
Lopinavir/r not associated with improved mortality or time to recovery in severe COVID. N=199; possible smaller benefit, requires larger trial to test. https://t.co/qjbINjDDJg
RT @WesElyMD: New #COVID19 Trials- Tx w combo-anti-HIV drugs no-go in NEJM https://t.co/Vny89JejJT BUT open label of same Lopin-Ritonavir +…
@AjteMa @DrJovana лек за Сиду ради: https://t.co/xkU57dSGkd
Ağır Kovid-19 hastalarının lopinavir-ritonavir ile tedavisinin standart bakımın ötesinde bir yarar sağlamadığı bildirildi. https://t.co/JDUOtO2UX8
RT @WesElyMD: New #COVID19 Trials- Tx w combo-anti-HIV drugs no-go in NEJM https://t.co/Vny89JejJT BUT open label of same Lopin-Ritonavir +…
RT @WesElyMD: New #COVID19 Trials- Tx w combo-anti-HIV drugs no-go in NEJM https://t.co/Vny89JejJT BUT open label of same Lopin-Ritonavir +…
5-7-2020: Bad news from China plus the U.K. plus the U.S. for the extremely effective anti-HIV drug combo, Kaletra (lopinavir plus ritonavir), for treating COVID-19: https://t.co/W1aGFHlRkw https://t.co/KqZmxy1nqJ https://t.co/yVwZJqDdsV
Why even publish? 1) They find that the study was underpowered. 2) Remdesivir became available for a trial. 3) Discontinued study #covid19 #wastemytime https://t.co/BPugUtuxdC
conclusion in paper: "no benefit was observed with lopinavir-ritonavir treatment beyond standard care. "
Core Pubmed: A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.: Related Articles A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 05… https://t.co/aDOEV7dp3s #coronavirus #SARS_CoV_2
RT @WesElyMD: New #COVID19 Trials- Tx w combo-anti-HIV drugs no-go in NEJM https://t.co/Vny89JejJT BUT open label of same Lopin-Ritonavir +…
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 » https://t.co/spyPNL3x7G Lopinavir–Ritonavir treatment did not significantly accelerate clinical improvement, reduce mortality, or diminish throat viral RNA detectability in patien
New #COVID19 Trials- Tx w combo-anti-HIV drugs no-go in NEJM https://t.co/Vny89JejJT BUT open label of same Lopin-Ritonavir + Ribavirin & Interferon-B1b Lancet 6 sites (N=127) may shorten viral shedding & Hosp LOS. https://t.co/bHbnwjBGAZ. Trial de
@V_MadnessMaster Докторе, плашим се да су знали за терапију од првог дана: https://t.co/xkU57dSGkd Јесте слушали др Монтењеја о деловима РНК вируса ХИВ у РНК вируса SARS-CoV-2
How about the combination of #remdesivir with #Kaletra -there was a weak signal in the NEJM trial for early patients put on treatment early? https://t.co/WS6MrFNouW
@radiokeller @RozehnalMd @PulmCrit @Brief_19 there was a new one on May 7! that's the one i'm referring to https://t.co/NfZl5djxrl
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe #COVID19 https://t.co/XtAPQeliMT vía @NEJM https://t.co/hsKhtLPBuX
あれっ、これって前々回の jjclipじゃないの? A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | NEJM https://t.co/Jouqe1OLWX
RT @rbganatra: 23/ These authors recently published a well-designed RCT on lopinavir-ritonavir in @NEJM that was also underpowered, but for…
RT @jsenior64: Hasta ahora en COVID-19: Lopinavir-ritonavir no sirve https://t.co/AZIIqWZDmV
23/ These authors recently published a well-designed RCT on lopinavir-ritonavir in @NEJM that was also underpowered, but for a different reason (the control group improved faster than expected). This did not happen in this study. https://t.co/UpGHl6q1F3
RT @TLawanson: Results 4rm a RCT of LPV/r Rx of severe COVID-19 patients: improvement in mortality of 5.8% vs ctrl grp @28Days, median time…
Results 4rm a RCT of LPV/r Rx of severe COVID-19 patients: improvement in mortality of 5.8% vs ctrl grp @28Days, median time to clinical improvement of 1 day compared to ctrl grp. No sig. difference in VL. A clear benefit can't be established with LPV/r Rx
RT @jsenior64: Hasta ahora en COVID-19: Lopinavir-ritonavir no sirve https://t.co/AZIIqWZDmV
#LopinavirRitonavir (#Kaletra) has had neutral effect on clinical outcomes in other #COVID19 #RCTs (eg below), so this has to be borne in mind as comparator didn’t include a placebo. https://t.co/5GoPBgHSFA
RT @Tony_Calles: 🦠 #COVID19 and #Statistics 📊 Brilliant letter to the @NEJM of 3 great spanish oncologists regarding results' interpretatio…
RT @Tony_Calles: 🦠 #COVID19 and #Statistics 📊 Brilliant letter to the @NEJM of 3 great spanish oncologists regarding results' interpretatio…
RT @Tony_Calles: 🦠 #COVID19 and #Statistics 📊 Brilliant letter to the @NEJM of 3 great spanish oncologists regarding results' interpretatio…
なんか、知らんうちにアビガン効くかもっていう論文が取り下げられてやっぱ効かへんって言ってんねんけど A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | NEJM https://t.co/n5A9TNgrnH
RT @jsenior64: Hasta ahora en COVID-19: Lopinavir-ritonavir no sirve https://t.co/AZIIqWZDmV
@Faisal_Alsayegh وهذه أيضاً الدراسة من نيجم قبل يومين تشير إلى أن Lopinavir-Ritonavir غير فعّال في مواجهة COVID-19 https://t.co/yE7LT87awW
RT @Tony_Calles: 🦠 #COVID19 and #Statistics 📊 Brilliant letter to the @NEJM of 3 great spanish oncologists regarding results' interpretatio…
RT @jsenior64: Hasta ahora en COVID-19: Lopinavir-ritonavir no sirve https://t.co/AZIIqWZDmV
RT @Tony_Calles: 🦠 #COVID19 and #Statistics 📊 Brilliant letter to the @NEJM of 3 great spanish oncologists regarding results' interpretatio…
RT @jsenior64: Hasta ahora en COVID-19: Lopinavir-ritonavir no sirve https://t.co/AZIIqWZDmV
RT @jsenior64: Hasta ahora en COVID-19: Lopinavir-ritonavir no sirve https://t.co/AZIIqWZDmV
RT @jsenior64: Hasta ahora en COVID-19: Lopinavir-ritonavir no sirve https://t.co/AZIIqWZDmV
RT @jsenior64: Hasta ahora en COVID-19: Lopinavir-ritonavir no sirve https://t.co/AZIIqWZDmV
RT @jsenior64: Hasta ahora en COVID-19: Lopinavir-ritonavir no sirve https://t.co/AZIIqWZDmV
RT @jsenior64: Hasta ahora en COVID-19: Lopinavir-ritonavir no sirve https://t.co/AZIIqWZDmV
RT @jsenior64: Hasta ahora en COVID-19: Lopinavir-ritonavir no sirve https://t.co/AZIIqWZDmV
Hasta ahora en COVID-19: Lopinavir-ritonavir no sirve https://t.co/AZIIqWZDmV
@MikeTRose @laragooo @ASlavitt Yeah same, I just have much time to kill and read a lot. The German Article also suggested that there are possible side effects like hepatitis C from the HIV medication in this cocktail. Here is the full article from the New
@Dr_Almohammed على الاقل اول دراسه تحس ان الGraphs واضحه من دون لخبطه احصائيه! مثل اي دواء ضد الفيروسات فائدته في البدايه فقط ، كوريا الجنوبية كانت تتكلم عن Kaletra وتأثيره .ظهرت دراسة تشير لعدم فعالية مضادات الفيروسات بعد فتره https://t.co/PVyxTaNimD لكن
Si lopinavir/ritonavir no presento mejorías versus placebo https://t.co/rkhwUF2772 y sumarle interferón parecería ser más eficaz que no hacerlo https://t.co/yN3itMA2dP Cuál seria el diseño más racional de la fase 3?
RT @Tony_Calles: 🦠 #COVID19 and #Statistics 📊 Brilliant letter to the @NEJM of 3 great spanish oncologists regarding results' interpretatio…
RT @Tony_Calles: 🦠 #COVID19 and #Statistics 📊 Brilliant letter to the @NEJM of 3 great spanish oncologists regarding results' interpretatio…
"A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19": https://t.co/RL7QbBT7GS
RT @sahaider75: 3 🔴فيما بعد مهد ذلك لاستخدام توليفة من المركبين Lopinavir + Ritonavir و روسيا بعد تصاعد الاصابات فيها بشكل كبير توصي باستخد…
RT @Tony_Calles: 🦠 #COVID19 and #Statistics 📊 Brilliant letter to the @NEJM of 3 great spanish oncologists regarding results' interpretatio…
RT @Tony_Calles: 🦠 #COVID19 and #Statistics 📊 Brilliant letter to the @NEJM of 3 great spanish oncologists regarding results' interpretatio…
🦠 #COVID19 and #Statistics 📊 Brilliant letter to the @NEJM of 3 great spanish oncologists regarding results' interpretation of the negative trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe #COVIDー19 negative ≠ no evidence of efficacy https:/
3 🔴فيما بعد مهد ذلك لاستخدام توليفة من المركبين Lopinavir + Ritonavir و روسيا بعد تصاعد الاصابات فيها بشكل كبير توصي باستخدام المركب مؤكدة نجاحه في تجاربها السريرية الليكم الرابطين: 1.https://t.co/xZ0JsXuMu4 2.https://t.co/CJoSfHXCgn د. حيدر سلمان
COVID19 tedavisinde lopinavir–ritonavir tedavisinde beklenen sonucu göstermedi. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | NEJM https://t.co/kVWhheHxkW
RT @nnago: 以下の論文でもどうぞ。 https://t.co/3ccGnTQsmI https://t.co/UZtiBfukuC
以下の論文でもどうぞ。 https://t.co/3ccGnTQsmI https://t.co/UZtiBfukuC
RT @DanielUribeF: En pacientes adultos hospitalizados con #COVID19 grave, no se documentó beneficio alguno con lopinavir-ritonavir, más all…
RT @IntraMednet: Publicado hoy en NEJM: "En pacientes adultos hospitalizados con #Covid-19 grave, NO se observó ningún beneficio con el tra…
RT @ConocimientoCO3: Hoy @NEJM publica ECAs sobre #lopinavir-#ritonavir en pacientes hospit x #COVID19 https://t.co/mx0MF7HapS Entre sus co…
RT @ryoma_tanaka: 結論は、Lopinavir-RitonavirがCOVID-19には無効ってことなんですけど、このRCTは武漢で2020年1月18日から行われているんですね!このスピード感はスゴいです。 https://t.co/0Fnp8eFjC8
(NEJM) Ensayo abierto de lopinavir-ritonavir en adultos hospitalizados con covid-19 grave https://t.co/6ymIaTtCY3 https://t.co/XDBzQqOCjI
RT @rincondesisifo: (NEJM) Lopinavir-ritonavir en pac ingresados con #COVID19 en estado grave https://t.co/XdsuVvn7HB ECA abierto https://t…
Essai #lopinavir - #ritonavir contre #COVID19 A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | NEJM https://t.co/0IccdD6zCE